Anaferon (pediatric formulation) administered in the therapeutic-and-prophylactic regimen to mice receiving intranasally 100% infecting dose of A/California/07/2009(H1N1)v influenza virus exhibited an antiviral effect and 10-fold reduced the production of influenza virus in the lungs of infected mice on days 4, 6, and 8 after infection compared to the control (distilled water). The efficiency of Anaferon (pediatric formulation) administered before and after infection with A/California/07/2009(H1N1)v influenza virus was not inferior to the use of Tamiflu after infection.
Article PDF
Similar content being viewed by others
References
J. Dotis and E. Roilides, Hippokratia, 13, No. 3, 135–138 (2009).
R. Jain and R. D. Goldman, Pediatr. Emerg. Care., 25, No. 11, 791–796 (2009).
J. C. Hierholzer and R. A. Killington,Virology Methods Manual., Eds. B. W. J. Mahy and H. O. Kangro. London (1996).
National Research Council. Guide for the Care and Use of Laboratory Animals., 7th ed., Washington D.C. (1996).
S. M. Zimmer and D. S. Burke, N. Engl. J. Med., 361, 279–285 (2009).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Shishkina, L.N., Skarnovich, M.O., Kabanov, A.S. et al. Antiviral Activity of Anaferon (Pediatric Formulation) in Mice Infected with Pandemic Influenza Virus A(H1N1/09). Bull Exp Biol Med 149, 612–614 (2010). https://doi.org/10.1007/s10517-010-1006-0
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10517-010-1006-0